First Trials Report Reveals Uneven State of China Drug Development
More Approvals But Fewer Completions
Growing over 9% and domestic study sponsors take over 70% of the drugs in different stages, China clinical study sector attracts renewed interests post COVID, but underneath an uneven and less efficient field, noted a just released regulatory report.
